Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Nebulized Platelet-derived Extracellular Vesicles Attenuate Cigarette Smoke-induced Murine Emphysema Via Immunoregulation
Wang, Supeng, Stalboerger, Paul G., Paradise, Christopher J. , MaCranor, B., Daher, A., Du, D., Behfar, Atta , Paradise, C., Vassallo, R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3050-A3050

10.1164/ajrccm.2025.211.abstracts.a3050 Get It

Abstract Rationale: We previously reported (PMID: 38325750) that a nebulized exosome product isolated from human platelets (PEP) attenuated murine cigarette smoke (CS)-induced emphysema. To further elucidate the mechanism by which PEP attenuates CS-induced effects in the murine lung, emphysema was induced, and mice were treated with PEP or placebo (saline). Immune and cellular mechanisms affected by PEP were then evaluated in this system. Methods: C57BL6 female black mice were exposed to CS 5 days a week for 3 months and then randomized into PEP-treated or placebo groups. CS-exposed mice were treated with 3 mL of 7.5 mg/mL PEP (∼1 x 1010 extracellular vesicles per mL) or 0.9% saline by nebulization 3 times a week for an additional 4 weeks, using a nose-sealed, pressure and humidity-controlled inhalation tower for 30 minutes. Lung compliance, cutaneous O2 saturation, mean linear intercepts, and lung inflammation were measured during and after the study. Lung tissue was further analyzed by immunostaining, and gene expression analyses to elucidate the molecular mechanisms of PEP's action. Inflammatory and immune regulatory cell markers evaluated included CD4 (CD4+ T lymphocytes), CD4/Foxp3 (T regulatory – Treg) cells, S100A9 (interstitial lung macrophages), and myeloperoxidase (MPO) for neutrophils. Results: Histologic review of lung tissue sections by mean linear intercept counts confirmed prior findings and showed a significant reduction in the free distance of chronic CS exposure-induced alveolar space enlargement in PEP-treated mice (P=0.003). In addition, lung inflammation scores showed a significant overall reduction of the lymphocytic infiltrates in PEP-nebulized lungs compared to the CS-exposed placebo control group (P<0.0001). Further analysis of the immune cell infiltrates revealed increased FOXP3+CD4+ T regulatory cells within the lymphocytic infiltrates (P<0.0001) and decreased S100A9+ interstitial lung macrophages (p=0.0002) and MPO+ neutrophils (p=0.005) in PEP nebulized lungs compared to the placebo controls. PEP-treated mice had similar oxygen saturation levels when compared to the CS control group (94.7±1.47 vs. 95.4±.1.6 respectively). Conclusions: In addition to validating prior findings on the effect of nebulized PEP in mitigating CS-induced murine lung injury and emphysema, the current data suggests an immunoregulatory role for PEP by decreasing inflammatory macrophage and neutrophil infiltration while augmenting anti-inflammatory Treg cell numbers in the lung.
Lower Lobe Mucus Plug Distribution is Associated With Increased Risk for Future Acute Exacerbations Among Tobacco-exposed Persons
Mettler, S.K., Campo, M. Iturrioz, Yen, A., Sonavane, S., Wang, Wei , Cho, M.H. , Mettler, Sofia K. , Wan, Emily S. , Borgaonkar, Ruchita , Nardelli, Pietro , Grumley, Scott , Estépar, R. San José , Díaz, Alejandro A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2944-A2944

10.1164/ajrccm.2025.211.abstracts.a2944 Get It

Abstract Introduction / Rationale Mucus plugs (MPs) on chest computed tomography (CT) are associated with increased respiratory symptoms, worse lung function, and elevated mortality and acute exacerbations among individuals with GOLD2-4 COPD. Whether mucus plug distribution in the upper versus lower lobes differentially impacts future acute exacerbations (AEs) has been incompletely explored. Methods Data from current and former tobacco users, ages 40-80, with ≥10 pack-years, at the enrollment visit in COPDGene were analyzed. MPs were visually-assessed on chest CTs using a sequential reading system; the MP score was calculated as the number of bronchopulmonary segments with plugs (range 0-18). Among subjects with MPs, the percent of lower lobe MPs (%LLMPs) was calculated as the number of bronchopulmonary segments in the right and left lower lobes divided by the total number of bronchopulmonary segments (range 0-100%). Moderate-to-severe AEs were assessed prospectively biannually for up to 15.5 years. Zero-inflated Poisson regression, adjusting for age, sex, BMI, race, smoking status, pack-years, FEV1% predicted, history of AEs (year prior to enrollment), and clinical center assessed the relationship between %LLMPs, total MPs, and prospective AEs; duration of follow-up was included as the offset. Subgroup analyses by lung function category (GOLD0, GOLD 1-4 COPD, and Preserved Ratio Impaired Spirometry, PRISm) were also performed using the same model. Results Among 10,198 tobacco-exposed individuals, 9,406 subjects (mean age 59.7±9.0, 53.4% male, 68% non-Hispanic white) had chest CT scans scored for MPs. The overall prevalence of MP>0 was 30.4%, with an average MP score of 0.78±1.88 and average %LLMP of 48%±39%. The prevalence of MPs varied by lung function category (20.1% GOLD0, 26.2% PRISm, 40.8% COPD) as did the mean MP score (0.28±0.93 GOLD0, 0.49±1.38 PRISm, 1.30±2.42 COPD) (Figure 1). The %LLMP also varied by lung function category (33%±39% GOLD0, 38%±37% PRISm, 57%±37% COPD). Among subjects with MPs>0 (n=2,857), higher %LLMP was associated with a significantly increased risk for future AEs (adjusted rate ratio (aRR) [95%CI]= 1.11[1.05-1.17]; Figure 1). Subgroup analyses by lung function category supported a significant association between increased %LLMP and future AEs in GOLD0 (aRR 1.45 [1.25-1.69]), but not in the COPD or PRISm subgroups (Figure 1). Conclusions A higher proportion of lower lobe mucus plugs is significantly associated with increased risk for future AEs among tobacco-exposed persons. Despite having the lowest burden of MPs, the highest risk for prospective AEs with increasing %LLMP was observed in the subgroup with normal spirometry (GOLD0).
Leveraging Disease Relevant Transcriptomes From TOPMed LTRC Improves Polygenic Transcriptome Risk Prediction for COPD
Hu, Xin , Ardlie, Kristin , Lange, Leslie A., Lange, Ethan M. , Meyers, D.A., Bleecker, ER, Ortega, V.E., Silverman, Edward, Wheeler, Harry E., Liu, D., Cho, M.H., Barr, R. Graham , Kim, K., Wang, Li , Khunsriraksakul, Chachrit , Lappalainen, Tuuli , Aguet, François , Rich, Stephen S. , Rotter, Jerome I. , Meyers, D.A., Moll, Matthew , Castaldi, Peter J. , Hersh, Craig P. , Wheeler, H.E., Im, Hae Kyung , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2512-A2512

10.1164/ajrccm.2025.211.abstracts.a2512 Get It

Abstract RATIONALE: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality worldwide. We previously published the polygenic transcriptome risk score (PTRS) which uses the cumulative effect of predicted gene expression to construct genetic predictors for complex diseases, and we demonstrated the value of PTRS for COPD built on Genotype-Tissue Expression (GTEx) Lung tissue with significantly improved cross-ancestry portability. However, the postmortem collection and lack of lung disease status on GTEx samples likely affect results. We hypothesized that the performance of PTRS will be improved by using disease-relevant expression quantitative trait loci (eQTLs) to construct the score. Here, we aimed to improve performance of PTRS by leveraging disease-relevant eQTLs. METHODS: We constructed two transcriptome prediction models, Elastic Net (EN) and Prediction Using Models Informed by Chromatin conformation and Epigenomics (PUMICE), using TOPMed lung RNA-seq data from the Lung Tissue Research Consortium (LTRC), which included COPD patients undergoing lung surgery. We compared their performance with two published models built on RNA-seq from GTEx Lung tissue, GTEx-EN and GTEx-PUMICE. We first integrated each of four transcriptome models with multi-ancestry GWAS of FEV1/FVC ratio (Shrine et al. 2023) to generate transcriptome-wide association study (TWAS) results, which produced trait-associated genes. Pathway analysis was then conducted on significant TWAS genes. Finally, the PTRS was computed on TWAS genes that were included in the top 20 significantly enriched pathways. We tested performance of PTRS in race-stratified analysis for moderate-to-severe and severe COPD in COPDGene. RESULTS: Our models produced more significant TWAS genes (FDR<0.05) and had more overlaps with genes identified for FEV1/FVC ratio from Shrine et al. 2023 compared to two GTEx models (Fig. A). Additionally, our models had significantly higher AUC for predicting both moderate-to-severe and severe COPD in race-stratified analysis. The mean AUC from LTRC-EN for predicting severe COPD was 0.57 and 0.55 respectively for EUR and AFA, which was significantly higher than mean AUC of 0.54 and 0.51 from GTEx-EN (Delong p-value=8.15x10-10 for EUR and 1.42x10-3 for AFA) (Fig. B). Similarly, the PTRS derived from our models produced higher Odds Ratios (OR) per standard deviation. The mean OR from LTRC-PUMICE for moderate-to-severe COPD was 1.25 and 1.18 respectively for EUR and AFA, while it was 1.17 and 1.12 from GTEx-PUMICE (Fig. C). CONCLUSIONS: Our study demonstrates the value of leveraging disease-relevant RNA-seq to construct transcriptome prediction models and their improvement on identifying lung function genes and predicting COPD across ancestries.
Study of Soy Isoflavones (SOYA) Responder Analysis Among Patients Who Have 4G4G/4G5G Serine Protease Inhibitor Family E Member 1 (SERPINE1) Genotypes
Fowler, John R. , Cardet, J.C., Mhaskar, Rahul , Baptist, Alan P. , Dixon, Anne E. , Hanania, N.A., Israel, Elliot , Garrow, O.J., Moy, James N., Riley, Isaretta , Wang, J.G., Fowler, J., Nguyen, D.T., Casale, Thomas B. , Chiarella, Sergio E. , Garrow, Olivia Johnson, Nyenhuis, Sharmilee Maria , Smith, Lewis J. , Wu, Timothy , Cho, Seong , Kumar, Rajesh

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1344-A1344

10.1164/ajrccm.2025.211.abstracts.a1344 Get It

Abstract RATIONALE: 4G4G/4G5G SERPINE1 genotypes produce high concentrations of plasminogen activator inhibitor-1 and are associated with worse asthma outcomes. A secondary analysis of the American Lung Association (ALA) SOYA trial showed that soy isoflavones significantly reduced asthma exacerbations versus placebo among patients with 4G4G/4G5G SERPINE1 genotypes. We hypothesized that baseline characteristics predict optimal responders to soy isoflavones among this subgroup. METHODS: ALA-SOYA was a randomized controlled trial that tested the efficacy of soy isoflavones vs. placebo for reducing asthma exacerbations among adolescents and adults with symptomatic asthma. In this responder analysis among participants with 4G4G/4G5G SERPINE1 genotypes, baseline demographic and clinical characteristics were tested for effect modification of the treatment assignment (soy/placebo) on the primary outcome of annualized number of asthma exacerbations using interaction terms in negative binomial regression models, with a significance threshold of p-interaction=0.15. RESULTS: Data were available for n=168 participants. Soy reduced the annualized number of asthma exacerbations relative to placebo among patients with 4G4G/4G5G SERPINE1 genotypes (incident rate ratio (IRR)=0.37, 95% confidence interval (CI): 0.15-0.90, p=0.028). Self-reported adherence to baseline controller therapy was the only significant effect modifier of this association (interaction p=0.115), with those using inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) controller therapy at least twice weekly experiencing reductions in asthma exacerbations with soy versus placebo (IRR = 0.25, 95% CI: 0.09-0.69; p= 0.007) but not among those using ICS/LABA controller therapy less frequently (IRR = 1.33, 95% CI: 0.22-8.02; p= 0.757). CONCLUSION: Soy isoflavones reduce asthma exacerbations among patients with the 4G4G/4G5G SERPINE1 genotypes and are most effective in those with greater adherence to asthma controller therapy regimens.
Clinical and pathological spectrum of disease severity among patients with acute liver failure (ALF) undergoing deceased donor liver transplantation
Tujios, Shannan R. , Sussman, Norman , Rakela, Jorge , Ganger, Daniel , Bass, Nathan M., Reuben, Adrian , Stravitz, R. Todd, Wang, Hanlin , Peng, Lan, Yeh, Matthew M., Hatfield, Bryce , Lee, William M. , Group, for the Acute Liver Failure Study, Rakela, Jorge L, Lee, William M , Rule, Jody A. , Kleiner, David Erwin , Choi, Eun-Young Karen , Yang, Guang‐Yu , Gill, Ryan M. , Fontana, Robert J. , Group, for the Acute Liver Failure Study

Mayo Clinic

Liver Transplantation | May 9, 2025 | Volume: 31 | Issue: 11 | Pages: 1368-1378

10.1097/lvt.0000000000000634 | PMID 40341552 Get It

Listing and transplanting patients with acute liver failure (ALF) is challenging, requiring rapid assessment of the likelihood of recovery. The availability of a large number of ALF liver explants, along with their clinical data, afforded an opportunity to retrospectively evaluate liver transplantation (LT) decision-making. We hypothesized that, with the benefit of hindsight, a small number of patients might have recovered without LT. Three hundred liver explants from ALF patients of varying etiologies who had undergone LT over 22 years in the Acute Liver Failure Study Group registry were reviewed for histopathological features and degree of necrosis by a committee of 8 hepatopathologists. A second committee of 8 experienced transplant hepatologists independently reviewed clinical data on these same 300 patients and retrospectively scored the likelihood that each patient required transplantation. Only 3 (1%) of those reviewed by the Clinical Committee were considered to “Definitely” not require liver grafting, while an additional 10 (3.3%) were deemed to “Possibly” not require transplantation (Not Likely Group, N=13). There was no difference in the degree of necrosis in explants in these groups, when compared to the remaining Likely Group, N=287 (95.6%), except in acetaminophen (APAP)-associated ALF, where the degree of necrosis was more uniformly graded as severe, correlating with the need for transplantation. Virtually every patient undergoing LT for ALF retrospectively appeared to need their transplant, based on expert clinical consensus review. Overall, there was poor correlation between clinical severity and apparent degree of necrosis seen in the 300 liver explants, except perhaps for APAP subjects.
Development of a Pentacistronic Ebola Virus Minigenome System
Zell, Brady N. , Swenson, Vaille A. , Wang, Lin , Barry, Michael A. , Yamaoka, Satoko , Lu, Shao‐Chia , Barry, Michael A , Zell, Brady , Ebihara, Hideki

Mayo Clinic

Viruses | May 9, 2025 | Volume: 17 | Issue: 5 | Pages: 688

10.3390/v17050688 | PMID 40431699 Get It

Ebola virus (EBOV) causes severe disease outbreaks in humans with high case fatality rates. EBOV requires adaptation to cause lethal disease in mice by acquiring single mutations in both the nucleoprotein (NP) and VP24 genes. As an attempt to model mouse-adapted EBOV (MA-EBOV), we engineered novel pentacistronic minigenomes (5xMG) containing a reporter gene, VP40, and glycoprotein genes as well as the NP and VP24 genes from either EBOV or MA-EBOV. The 5xMGs were constructed and optimized, and the produced transcription- and replication-competent virus-like particles (trVLPs) were demonstrated to infect several cell lines. Introduction of the mouse-adaptation mutations did not significantly impact the replication and transcription of the 5xMG or the relative infectivity of the trVLPs in vitro. This work demonstrates the development of the 5xMG system as a new versatile tool to study EBOV biology.
Concurrent or subsequent lymphomatous effusion in large B-cell lymphoma portends a dismal prognosis: A multi-institutional study
Tang, Haiming , Xu, Jie , McCracken, Jenna , Li, Peng , Braunberger, Ryan C. , Wu, Xiaojun , Wang, Endi , Zhang, Qianyun , Soma, Lorinda, Zhang, Jingjing , Matsumoto, Nana , Xu, Mina L. , Pan, Zenggang , Tang, Haiming , Wang, Endi , Katz, Samuel G , Zhang, Jing Jing , Pan, Zenggang , Gisriel, Savanah D. , Ji, Yuan , Fang, Hong , Li, Shaoying , Xu‐Monette, Zijun Y. , Young, Ken H.

Mayo Clinic

American Journal of Clinical Pathology | May 9, 2025 | Volume: 164 | Issue: 3 | Pages: 390-401

10.1093/ajcp/aqaf057 | PMID 40581918 Get It

Abstract Objective Rare large B-cell lymphomas (LBCLs) present with concurrent or subsequent lymphomatous effusion (solid-effusion LBCL, SE-LBCL), which may have an inferior prognosis compared with their noneffusion counterpart. In addition, the relationship between SE-LBCL and human herpesvirus 8–negative effusion-based LBCL (EB-LBCL) remains unclear. Methods We collected 141 cases of SE-LBCL and a control cohort of 101 cases of stage IV solid-only LBCL. The clinicopathologic features were analyzed and compared between SE-LBCL and solid-only LBCL. Results Patients with SE-LBCL had a median age of 67 years with a male-to-female ratio of 1.3:1. Eighty-six patients had concurrent solid lymphoma and lymphomatous effusion, whereas 55 developed lymphomatous effusion subsequently. Most cases involved the pleural cavities (79%, 112/141), followed by the peritoneal (21%, 29/141) and pericardial (11%, 16/141) cavities. BCL6, CD10, and MUM1 were expressed in 77% (90/117), 46% (60/130), and 61% (58/95) of cases, respectively, and 58% (71/123) were subclassified into the germinal center B-cell (GCB) subtype. Rearrangements of BCL2, BCL6, and MYC were detected in 42% (31/73), 35% (22/63), and 40% (35/88), respectively, and 22% (19/87) had both MYC and BCL2 rearrangements. The patients with SE-LBCL had a dismal prognosis, with a median survival of 5.7 months, which was significantly worse than solid-only LBCL (147.5 months; P < .0001). Conclusions The pathologic features of SE-LBCL were similar to those of solid-only LBCL but distinct from those of EB-LBCL; in particular, lymphomatous effusion was an independently adverse prognostic factor in LBCL. Our study underscores the need for surveillance of lymphomatous effusion during LBCL staging and development of effective therapeutic regimens for SE-LBCL.
Efficacy and Morbidity of Heparin Infusion in Salvaging Autologous Breast Reconstruction Free Flaps
Odorico, Scott K. , Mazroua, Muhammad S., Wang, Leda, Day, Serena, Harless, Christin A., Martinez‐Jorge, Jorys, Vijayasekaran, Aparna , Mazroua, Muhammad Sabry, Awadallah, Andrew , Harless, Christin, Martinez-Jorge, Jorys, Awadallah, Andrew S. , Day, Serena J.

Mayo Clinic

Microsurgery | May 8, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1002/micr.70065 | PMID 40341693 Get It

ABSTRACT Background Abdominal‐based free flaps are the mainstay in autologous breast reconstruction. Their safety and consistency in outcomes are well‐documented. When flap compromise occurs, operative salvage is the gold standard. However, when—and if—to place these patients on heparin infusions is unclear. The goal of this study was to investigate abdominal‐based free flap compromise and compare outcomes with and without heparin infusion. Materials and Methods This was a single‐institution, multiple‐surgeon, retrospective chart review of patients undergoing autologous, abdominal‐based free flap breast reconstruction who experienced anastomotic compromise within a 6‐year period. Treatment and outcomes data collected include flap salvage, hematoma, seroma, surgical site infection (SSI), transfusion requirement, and length of hospital stay. Results Fifty‐one flaps had evidence of compromise. A total of 31 (60.8%) patients were placed on heparin infusions after experiencing anastomotic compromise, compared to 20 who did not receive heparin infusion. Thirty‐five patients (68.6%) underwent deep inferior epigastric perforator flaps. Twenty‐six patients (51%) experienced venous congestion, 22 patients (43.1%) experienced arterial compromise, and three (5.9%) experienced both. Twenty‐eight patients (54.9%) received tissue plasminogen activator; in the heparin infusion group, 21 patients (67.7%) received tissue plasminogen activator. The total salvage rate of compromised flaps was 94.1% (48/51). There was no significant difference between heparin infusion and standard cares in length of hospital stay, length of drains in‐place, successful salvage (93.5% vs. 95%), hematoma (19.4% vs. 15%), fat necrosis, SSI, hospital readmission (19.4% vs. 15%), and return rates to the operating room (48.4% vs. 50%). However, there was a significantly higher transfusion rate in patients receiving heparin infusion (38.7% vs. 10%). Of the 25 flaps with evidence of thrombosis, 72% were placed on heparin infusions while 28% were not; there was no significant difference in salvage rate in this sub‐group. Conclusions This review of autologous breast reconstruction free flap compromise provides evidence of similar safety profiles, with similar salvage rates, when comparing salvage with and without heparin infusion; there is a higher transfusion requirement when treating with heparin infusion.
EULAR /American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
Zhao, Yongdong , Oliver, Melissa , Schnabel, Anja , Wang, Zhaoyi , Marino, Achille , Aguiar, Cassyanne L. , Akikusa, Jonathan , Akça, Ümmüşen Kaya , Almeida, Beverley, Appenzeller, Simone , Balay‐Dustrude, Erin , Bilginer, Yelda , Cabral, David A. , Capponi, Martina , Donaldson, Nathan , Egeli, Buğra Han , Iyer, Ramesh S. , Jansson, Annette, Kostik, Inna , Kostik, Mikhail M. , Kovalick, Leonard K., Kozu, Kátia Tomie , Lee, Tzielan , Mahmood, Kamran , Muse, Ian, Mushkin, Alexander, Nowicki, Katherine D. , Nuruzzaman, Farzana , Pham, Trang Sophia, Potts, Lauren, Ramanan, Athimalaipet V., Rogers, Nathan D. , Grim, Andrew W. , Romano, Micol , Rosenwasser, Natalie , Sato, T. Shawn , Soep, Jennifer B. , Stern, Sara , Strauß, Timmy , Taneja, A. , Theos, Alexander C. , Tucker, Lori B. , Vogel, Lisa, Yasin, Shima , Wong, Stephen C. , Bouchalová, Kateřina , Hendry, Alison M., Cain, Kevin C. , Girschick, Hermann , Hedrich, Christian M. , Laxer, Ronald M. , Ferguson, Polly J. , Naden, Raymond P., Özen, Seza , Oliver, Melissa S , Akca, Ummusen Kaya , Appenzeller, Simone , Balay-Dustrude, Erin , Basiaga, Matthew L. , Kostik, Mikhail , Lapidus, Sivia K , Marrani, Edoardo , Mosa, Doaa Mosad , Nowicki, Katherine D , Pardeo, Manuela , Potts, Lauren , Ravelli, Angelo , Tucker, Lori B , Dedeoglu, Fatma , Hedrich, Christian M , Ozen, Seza , Wu, Eveline Y. , Başaran, Özge , Fox, Emily J., Insalaco, Antonella , Lapidus, Sivia , Lenert, Aleksander , Mahmood, Kamran, Mushkin, Alexander, Onel, Karen , Pham, Trang Sophia, Ramanan, Athimalaipet Vaidyanathan , Simonini, Gabriele , Dedeoğlu, Fatma

Mayo Clinic

Arthritis & Rheumatology | May 8, 2025 | Volume: 78 | Issue: 3 | Pages: 537-547

10.1002/art.43137 | PMID 40342207 Get It

Objective To develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR). Methods This international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients. Results The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anemia, C‐reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort. Conclusion These new classification criteria for pediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
Immunopipe: a comprehensive and flexible scRNA-seq and scTCR-seq data analysis pipeline
Wang, Panwen , Yu, Yue , Zhang, Shuwen , Kocher, Jean‐Pierre , Wang, Junwen , Asmann, Yan W. , Lin, Yi, Li, Ying , Kocher, Jean-Pierre A , Wang, Junwen , Yu, Yue, Dong, Haidong , Sun, Zhifu , Zeng, Hu , Mondello, Patrizia

Mayo Clinic

NAR Genomics and Bioinformatics | May 8, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1093/nargab/lqaf063 | PMID 40391086 Get It

Abstract Single-cell sequencing technologies provide us with information at the level of individual cells. Combining single-cell RNA-seq and single-cell TCR-seq profiling enables the exploration of cell heterogeneity and T-cell receptor repertoires simultaneously. Integrating both types of data can play a crucial role in enhancing our understanding of T-cell-mediated immunity and, in turn, facilitate the advancement of immunotherapy. Here, we present immunopipe, a comprehensive and flexible pipeline to perform integrated analysis of scRNA-seq and scTCR-seq data. In addition to the command line tool, we provide a user-friendly web interface for pipeline configuration and execution monitoring, benefiting researchers without extensive programming experience. With its comprehensive functionality and ease of use, immunopipe empowers researchers to uncover valuable insights from scRNA-seq and scTCR-seq data, ultimately advancing the understanding of immune responses and immunotherapy development.